Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

371
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
371
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

311
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
311
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

701
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
701

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The clinical utility of functional testing in fibroblasts to diagnose primary mitochondrial disease.

medRxiv : the preprint server for health sciences·2026
Same author

Adenotonsillectomy is associated with increased risk and disease activity in pediatric-onset multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Factors associated with delays in multiple sclerosis disease-modifying therapy initiation.

Multiple sclerosis journal - experimental, translational and clinical·2026
Same author

Longitudinal short-term assessments of single- and multi-protein disease activity biomarkers to determine reliability and the minimum detectable change in people with clinically stable RRMS.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Menopause is a physiological progression event for women with multiple sclerosis: Commentary.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Characteristics of myelin oligodendrocyte glycoprotein antibody-associated meningoencephalitis.

Multiple sclerosis journal - experimental, translational and clinical·2026
Same journal

Mind the gender gap: how defining head trauma increases reporting in women aged 30-50.

Frontiers in neurology·2026
Same journal

Traditional Chinese medicine interventions for post-stroke cognitive impairment: an evidence mapping.

Frontiers in neurology·2026
Same journal

Acupuncture is independently associated with improved recovery in Guillain-Barré syndrome: a prospective observational study.

Frontiers in neurology·2026
Same journal

A convergence of global epidemics: diabetes as a modulator of neurodegenerative and neuro-inflammatory disorders.

Frontiers in neurology·2026
Same journal

Lumbar puncture opening pressure, brain network hub integrity, and delirium in herpes simplex virus encephalitis: a prospective cohort study.

Frontiers in neurology·2026
Same journal

Sleep deprivation: a comprehensive review of multisystem impacts, underlying mechanisms, and emerging interventions.

Frontiers in neurology·2026
See all related articles

Related Experiment Video

Updated: Sep 7, 2025

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

10.4K

Therapeutic Advances in Multiple Sclerosis.

Jennifer H Yang1, Torge Rempe2, Natalie Whitmire1

  • 1Department of Neurosciences, University of California San Diego, San Diego, CA, United States.

Frontiers in Neurology
|June 20, 2022
PubMed
Summary
This summary is machine-generated.

Multiple sclerosis treatments have advanced significantly, with new therapies targeting immune responses and emerging options for remyelination. However, progressive MS remains challenging, necessitating a comprehensive overview of current therapeutic strategies.

Keywords:
demyelinationdisease modifying therapymultiple sclerosisneurodegenerationreview

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.4K
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

27.2K

Related Experiment Videos

Last Updated: Sep 7, 2025

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

10.4K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.4K
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

27.2K

Area of Science:

  • Neuroimmunology
  • Clinical Neurology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease impacting the central nervous system.
  • MS leads to substantial disability and significant healthcare costs.
  • Treatment paradigms for MS have undergone major evolution over 30 years.

Purpose of the Study:

  • To provide a comprehensive review of the current therapeutic landscape for multiple sclerosis.
  • To highlight advancements in disease-modifying therapies for MS.
  • To discuss challenges and emerging treatments for progressive MS.

Main Methods:

  • Review of current literature on MS therapeutics.
  • Analysis of disease-modifying therapies targeting various immune mechanisms.
  • Examination of novel and emerging treatment strategies.

Main Results:

  • Significant progress in high-efficacy therapies modulating immune responses.
  • Emerging treatments include BTK inhibitors, stem cell transplantation, remyelination, and neuroprotection.
  • Therapeutic development for progressive MS faces challenges with limited efficacy in current agents.

Conclusions:

  • The MS therapeutic landscape is diverse and rapidly evolving.
  • New therapies offer improved management for relapsing forms of MS.
  • Further research is crucial for effective progressive MS treatments.